15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Immunome Inc, 12 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $22.00 to $40.00, a moderate spread. The average target of $33.17 sits 43% above the current $23.20. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 10 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.56 next quarter toward $-2.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy00%
Buy12100%
Hold00%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Immunome Inc.
As of Jul, 12 of 12 firms rate IMNM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IMNM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.56
Range $-0.73 – $-0.48 · 12 analysts · -14% YoY
Next period, 12 analysts expect Immunome Inc to earn $-0.56 a share (range $-0.73 – $-0.48), versus $-0.65 a year earlier. Full-year consensus is $-2.12, growing to $-2.12 the year after.
REVENUE · NEXT QUARTER
$166.7K
Range $0 – $2.0M · 12 analysts
Revenue is expected to reach $166.7K (range $0 – $2.0M). Full-year consensus is $2.7M, rising to $64.6M next year.
Top analysts covering Immunome Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMNM.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$35.00+50.9% to target
Overall win rate
55%
+ Follow
#2
David Nierengarten
Wedbush · Rank #115
Buy
$31.00+33.6% to target
Overall win rate
41%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #167
Buy
$33.00+42.3% to target
Overall win rate
50%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$40.00+72.5% to target
Overall win rate
38%
+ Follow
#5
SL
Sudan Loganathan
Stephens & Co.
Buy
$30.00+29.3% to target
Coverage
—
+ Follow
IMNM stock forecast FAQ
What is IMNM's average 12-month price target?+
The 12 analysts with a live target average $33.17 for Immunome Inc over the next 12 months, ranging from a $40.00 high to a $22.00 low.
Is IMNM stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 12 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IMNM?+
The Street-high target is $40.00 (HC Wainwright & Co.), and the Street-low is $22.00 (JP Morgan). The average of all 12 active targets is $33.17.
How many Wall Street analysts cover IMNM?+
12 analysts have an active rating on Immunome Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMNM?+
Among analysts who currently cover IMNM, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $35.00 target.
What is Immunome Inc's projected EPS for next quarter?+
The consensus estimate is $-0.56 per share (range $-0.73 – $-0.48) across 12 analysts. Full-year EPS is projected at $-2.12, rising to $-2.12 the following year.
How much revenue is Immunome Inc expected to report next quarter?+
Consensus revenue is $166.7K (range $0 – $2.0M). Full-year revenue is projected at $2.7M, growing to $64.6M next year.
Have analysts been upgrading or downgrading IMNM lately?+
As of Jul, 12 of 12 firms rate IMNM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMNM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
